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Abstract
In contrast to endocrine-sensitive and HER2-positive breast cancer, novel agents capable of treating
advanced triple negative breast cancer (TNBC) are lacking. PARP (Poly-(adenosine diphosphate
[ADP]-ribose) polymerase) inhibitors are emerging as one of the most promising ‘targeted’
therapeutics to treat TNBC, with the intended ‘target’ being DNA repair. PARP's are a family of
enzymes involved in multiple cellular processes including DNA repair. TNBC shares multiple
clinico-pathologic features with BRCA-mutated breast cancers which harbor dysfunctional DNA
repair mechanisms. Investigators hypothesized PARP inhibition, in conjunction with the loss of
DNA-repair via BRCA-dependent mechanisms, would result in synthetic lethality and augmented
cell death. This hypothesis has borne out in both preclinical models and in clinical trials testing PARP
inhibitors in both BRCA-deficient and TNBC. The focus of this review will include an overview of
the preclinical rationale for evaluating PARP inhibitors in TNBC, the presumed mechanism of action
of this novel therapeutic class, promising results from several influential clinical trials of PARP
inhibition in advanced breast cancer (both TNBC and BRCA-deficient), proposed mechanisms of
acquired resistance to PARP inhibitors, and, finally, conclude with current challenges and future
directions for the development of PARP inhibitors in the treatment of breast cancer.
Introduction
Inhibition of PARP (Poly-(adenosine diphosphate [ADP]-ribose) polymerase) is emerging as
one of the most exciting and promising ‘targeted’ therapeutic strategies to treat advanced triple
negative breast cancer – the intended ‘target,’ being DNA repair. Diagnosed in an estimated
180,000 women worldwide, triple negative breast cancer (TNBC) is an aggressive subset of
breast cancer that lacks expression of the estrogen and progesterone receptors (ER and PR)
and the HER2 protein(1). TNBC, classified as basal-like by gene expression 80% of the time,
is characterized by distinct risk factors, aggressive and early patterns of metastases, unique
molecular characteristics, association with BRCA1 mutations, a relative lack of targeted
therapeutics and poor prognosis(2-9).
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In contrast to endocrine sensitive and HER2 positive breast cancer, novel agents capable of
treating advanced triple negative breast cancer are at present lacking. Currently-available
therapies are limited to cytotoxic chemotherapy with or without the addition of the anti-
angiogenic agent, bevacizumab (Avastin, Genentech). Despite improvements in progression
free survival when combining bevacizumab with paclitaxel among patients with HER2-
negative advanced breast cancer (11.8 versus 5.9 months), absolute improvements for the triple
negative subset were more limited (9 versus 5 months)(10,11). Similarly, while there was a
progression-free survival benefit of adding ixabepilone (Ixempra, Bristol Meyer Squibb), a
newer generation microtubule stabilizing agent, to capecitabine chemotherapy among the triple
negative subset (4.1 versus 2.1 months), the benefit was still only modest in part based on poor
baseline outcomes among women with advanced breast cancer regardless of subtype (5.8
versus 4.2 months) (11,12).
Given the poor prognosis and high rate of visceral metastases (including central nervous system
recurrence) associated with TNBC, investigators have been actively searching for innovative
therapeutic strategies to effectively treat this aggressive disease(13,14). Building on the
observation that TNBC shares several clinical and pathologic characteristics with BRCA-
deficient breast cancers known to harbor deficient DNA repair mechanisms, PARP inhibitors
have been tested in early phase clinical trials among patients with advanced TNBC. Preliminary
results of phase II trials are encouraging and report improvements in response rates, progression
free (PFS) and overall survival (OS) when adding PARP inhibition to DNA-damaging
chemotherapeutics with minimal additional toxicity(15,16). We will review the preclinical
rationale for evaluating PARP inhibitors in triple negative (and BRCA-deficient) advanced
breast cancer, the presumed mechanism of action of this novel therapeutic class, promising
results from several influential clinical trials of PARP inhibition in advanced breast cancer
(both TNBC and BRCA-deficient), proposed mechanisms of acquired resistance to PARP
inhibitors, and, finally, conclude with current challenges and future directions for the
development of PARP inhibitors in the treatment of breast cancer.
DNA Repair as a Therapeutic “Target” and Proposed Mechanism of PARP
Inhibitors
DNA damage is an ongoing process resulting from both endogenous and exogenous
(environmental) assaults to the human genome. Endogenous forms for DNA damage arise from
spontaneous base changes, replication errors and oxygen-free radicals, while exogenous forms
include chemical mutagens, cytotoxic agents and both ultra-violet and ionizing radiation(17).
The genome is armed with multiple DNA repair mechanisms, including but not limited to
Mismatch Repair (MMR), Base Excision Repair (BER), Nucleotide Excision Repair (NER)
and Double Strand Break Repair (DSR). DNA double strand breaks are highly toxic to cells
and two main pathways contribute to their inherent repair – error-prone non-homologous end
joining (NHEJ) and error-free homologous recombination (HR, Figure 1a)(17-19). HR is
dependent on functional BRCA 1 and 2 pathways and BRCA maintains genome stability, at
least in part, by regulating HR according to the type of DNA damage(20-23). As follows,
germline mutations in either the BRCA1 or BRCA2 genes are associated with a high risk of
developing a number of cancers, including breast, ovarian, and prostate cancer(17,24,25).
When the BRCA-associated DNA repair pathway – namely HR – is lost or dysfunctional, repair
shifts toward alternate DNA repair mechanisms dependent on a unique class of enzymes, Poly-
(adenosine diphosphate [ADP]-ribose) polymerase (PARP).
PARP's are a family of enzymes involved in cellular processes such as genomic stability, DNA
repair, cell cycle progression, and apoptosis(26,27). PARP-1, a nuclear, zinc-finger,
deoxyribonucleic acid (DNA)-binding protein, localizes to DNA strand breaks as part of the
base excision repair (BER) process(28). Cell death from targeting two genes which, alone, do
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not result in cell death is termed “synthetic lethality.” Investigators hypothesized PARP
inhibition, in conjunction with the loss of DNA-repair via BRCA-dependent mechanisms,
would result in synthetic lethality and augmented cell death (Figure 1b) – a hypothesis that has
borne out in both preclinical models and the clinical trial arena.
It well-recognized that BRCA-deficient, basal-like (as defined by microarray) and triple
negative (as defined by immunohistochemistry [IHC]) breast cancers share clinical and
pathologic similarities, including high rates of p53 mutation, aneuploidy, high pathological
grade, and relative sensitivity to DNA-damaging chemotherapeutics (Table 1)(4,7,9,15,29,
30). Several mechanisms have been proposed to explain these similarities based on presumed
BRCA pathway and subsequent HR dysfunction in sporadic basal-like and TNBC. These
mechanisms may include (1) over-expression and copy number gain of ID4, a negative
regulator of BRCA1(31,32), (2) decreased expression of BRCA1 messenger RNA(32), (3)
BRCA1 gene promoter methylation(33) and (4) copy number aberrations affecting genes within
a ‘BRCA DNA Damage Response’ pathway(32). Each of these observations suggests a role
for defective HR DNA repair among sporadic TNBC and basal-like breast tumors providing
the basis for the term “BRCAness” of sporadic TNBC(34). Thus, the “BRCAness” of sporadic
TNBC has provided the rationale to test PARP inhibitors, not only in advanced BRCA-mutated
tumors, but also sporadic TNBC. Results from early phase clinical trials evaluating the efficacy
of PARP inhibitors in BRCA-mutated and TNBC, although preliminary, are quite promising
(15,35-37).
Preclinical Efficacy of PARP Inhibition in BRCA-deficient and TNBC/Basal-
like Breast Cancer Models
Two landmark preclinical studies report (1) feasibility of targeting DNA repair defects inherent
to BRCA mutant cell lines as a therapeutic strategy and (2) the acute sensitivity of BRCA-2
deficient embryonic stem cells to PARP inhibition due to deficiencies in HR(38,39). Farmer
et al. conducted a series of experiments illustrating a reduction in clonogenic survival of
BRCA-1 and BRCA2-deficient cell lines when transfected with a plasmid expressing a short
interfering RNA (siRNA) targeting PARP1. Chemical inhibition of PARP1 was more potent
in BRCA-1 and BRCA-2 deficient embryonic stem cells compared to heterozygous mutant and
wild-type cells. An in vivo BRCA-2 deficient murine model supported these findings(39).
Parallel studies conducted by Bryant et al. also demonstrated cell lines deficient in HR (via
defective XRCC2, XRCC3 and BRCA2) were highly sensitive to PARP inhibition. Treatment
of BRCA2-deficient cells lines with PARP inhibition induced gamma(γ)-H2AX foci, a marker
of DNA double strand breaks, and BRCA2 deficient tumors in a xenograft model were
susceptible to PARP inhibition(38). Taken together, results from these studies suggested a new,
mechanism-based approach for the treatment of patients with BRCA-1 and BRCA2-deficient
tumors. Importantly, models of sensitivity to PARP inhibition suggest that the key ingredient
is deficiency in HR, indicating that this approach may be more widely applicable in the
treatment of sporadic cancers sharing functional BRCA loss or other impairments of homologus
recombination.
As discussed above, BRCA-mutated, basal-like and TNBC share a number of clinico-
pathologic characteristics (Table 1). BRCA-1 and BRCA-2 mutation carriers, however,
comprise a minority of breast cancer cases(24,25). The “BRCAness” of TNBC, which is
classified as basal-like by cDNA microarray over 80% of the time(9,40), led investigators to
evaluate the sensitivity of PARP inhibition in breast cancer cell lines of varying subtypes (i.e.
luminal, basal, etc.) to not only determine subtype-specific sensitivity, but to further elucidate
the mechanism of cellular cytotoxicity.
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A series of informative preclinical studies evaluating DNA damage response pathways in breast
cancer cell lines of different subtypes report selective response of basal-like breast cancer cell
lines to PARP inhibition which may, in addition to defective HR, be due to inefficient base
excision repair (BER)(41). Oxidative DNA damage (ODD) constitutes a large majority of
endogenous DNA damage in human cells. DNA damage from reactive oxygen species usually
occurs as a single-base alteration repaired via BER. Investigators hypothesized that basal-like
and BRCA-1 mutated breast cancers share defects in maintaining genomic stability via aberrant
regulation of ODD. When a variety of breast cancer cell lines of a varying subtypes, including
luminal, basal-like and BRCA-1 mutated breast cancers were tested for sensitivity to H202, (as
an indicator of response to ODD), basal-like and BRCA1- mutated breast cancer cell lines were
most sensitive, thus, least effective in the repair of oxidative damage. (41).
A second set of parallel experiments concluded that the relative inefficiency of basal-like and
BRCA-1 mutated breast cancer cell lines to repair ODD was a result of defective BER(41).
Briefly, a BER assay involving BER-dependent expression of a GFP [green fluorescent
protein] reporter gene showed a relative decrease in GFP expression 24 hours following DNA
damage among basal-like and BRCA-1 mutated breast cancer cell lines when compared to
luminal breast cancer cell lines. Moreover, transfection of the BRCA-1 mutated cell line
SUM149 with wild-type BRCA1 resulted in a 4-fold increase in BER, while shRNA knock-
down of BRCA1 resulted in decreased BER. Inefficient BER repair was correlated with
sensitivity to PARP inhibition in vitro. In addition, using this same panel of cell lines, it was
shown that the basal-like cells were selectively sensitive to platinum and gemcitabine, and that
these drugs exhibited synergy when combined with a PARP inhibitor in basal-like but not
luminal breast cancer cell lines(42). This series of informative studies continues to shed light
on the complicated mechanism of action inherent to PARP inhibitors and provides a plausible
mechanism for the selective efficiency of PARP inhibitors in BRCA-mutated and basal-like
cell lines – an observation that has borne out in clinical studies.
PARP-inhibitors: Overview of Current Clinical Data
In parallel to strides in the preclinical arena, pharmacologic inhibition of PARP has translated
into advances in the clinical management of patients with TNBC and BRCA-deficient advanced
breast cancer. Historically, the treatment of advanced TNBC has been fraught with unique
challenges. Specifically, in contrast to endocrine sensitive and HER2-enriched breast cancer,
TNBC is characterized by a relative lack of “drug-able” targets, rapid recurrence in visceral
organs (including the CNS), and inherently poor prognosis(13,14). Based on elegant preclinical
rationale, PARP inhibitors are being tested in BRCA-deficient and TNBC and illustrate clinical
efficacy. Although there are several PARP inhibitors in early phase development (Table 2),
the lion's share of clinical experience has been with olaparib (AZD2281, AstraZenca/KuDOS)
and BSI-201 (BiPAR Sciences/Sanofi Aventis).
Olaparib
The efficacy of olaparib, an oral PARP inhibitor, among patients with BRCA-mutated advanced
solid tumors was initially reported in the phase I setting(35). In addition to standard dose-
escalation and pharmacokinetic/pharmacodyamic analyses, toxicity and efficacy were reported
among 60 patients with advanced tumors, a population enriched for BRCA-mutation carriers
(n = 22). Pharmacokinetic data indicated rapid absorption and elimination; pharmacodynamic
studies confirmed PARP inhibition in surrogate samples (peripheral-blood mononuclear cells
and plucked eyebrow-hair follicles) and tumor tissue. There was no obvious increase in adverse
effects among BRCA-mutation carriers. Objective anti-tumor activity was reported only in
mutation carriers (all heavily pre-treated for breast, ovarian or prostate cancer).
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A second phase II, multi-center, single-arm, sequential cohort design study sought to determine
the efficacy/tolerability of the olaparib among patients with BRCA1/BRCA2-deficient,
advanced breast cancer(43). Fifty-four patients were enrolled in one of two dose-based cohorts
(cohort 1 = 27 treated with 400mg orally twice daily; cohort 2 = 27 treated with 100mg orally
twice daily). The primary objective was objective tumor response (complete response [CR]
plus partial response [PR]). Secondary objectives included progression-free survival (PFS),
safety, and tolerability. At the time of progression, patients in cohort 2 were permitted to cross-
over to cohort 1. The majority of patients in both cohorts harbored BRCA1 mutations, 67% and
56%, respectively; a smaller proportion had BRCA2 mutations, 33% and 41%, respectively.
Over 50% of patients had TNBC and median number of prior therapies was 3. Overall response
rates were 41% and 22% among patients in cohort 1 and 2, respectively. PFS was 5.7 (4.6 –
7.4) months in cohort 1 and 3.8 (1.9 – 5.5) months in cohort 2. The most commonly reported
grade 3 adverse events were fatigue, nausea and vomiting. Treatment discontinuation due to
adverse events was uncommon.
Several Canadian studies are ongoing to define efficacy, mechanisms of resistance, and patient
population most likely to respond to olaparib. Canadian 20 study is a phase II study enrolling
4 cohorts of 91 patients with advanced breast or ovarian cancer: A) Ovarian, BRCA negative/
unknown, B) TNBC, BRCA negative/unknown, C) Ovarian, BRCA-mutated and D) Breast,
BRCA-mutated, ER - or +. Patients received olaparib 400 mg orally twice daily. Assessments
at eight weeks include imaging, tumor re-biopsy, blood collection and response assessment.
Although responses were seen in Arms A, C and D, Arm B closed early as no responses were
seen in 15 enrolled patients with sporadic TNBC. This trial is one of the first to report response
assessment for PARP inhibitors as a single agent to treat sporadic TNBC, and with limited and
unimpressive results further supports the use of combination PARP inhibitor plus
chemotherapy to treat patients with sporadic TNBC(44).
Canadian Study 11, a randomized, double-blind, multi-center study assessing efficacy of
olaparib in combination with paclitaxel in the 1st or 2nd line treatment of metastatic TNBC,
yielded notable toxicity patterns(45). In the phase I cohort, 8 of 9 patients required paclitaxel
dose modifications and 4 of 9 required olaparib dose modifications due to grade 2 – 4
neutropenia prompting the use of G-CSF rescue (granulocyte colony-stimulating factor) in
cohort 2. Overall response in cohorts 1 and 2 were 33% (3/9) and 40% (4/10), respectively.
Ongoing trials with olaparib and DNA-damaging chemotherapeutics (i.e. phase II, olaparib
with carboplatin in advanced BRCA-deficient and TNBC and phase I/II, olaparib with cisplatin
in the neoadjuvant treatment of TNBC) will shed light on this toxicity. Moreover, these trials
will further define whether or not dose-limiting neutropenia is specific to olaparib in
combination with paclitaxel or is more generalizable across the broader class of DNA-
damaging chemotherapeutics.
BSI-201
Initial safety, tolerability and efficacy of the intravenous PARP inhibitor, BSI-201, was
reported in a series of phase I studies as a single agent and in combination with several DNA-
damaging chemotherapeutics, respectively(46,47). A phase I study of BSI-201 in 23 heavily-
pretreated patients with advanced solid tumors report tolerability at doses ranging from 0.5
mg/kg – 8.0 mg/kg. A maximum tolerated dose (MTD) was not reached with the most common
side effects being fatigue (56%), nausea (47%), vomiting (39%), and constipation (21%).
PARP activity as measured in peripheral blood mononuclear cells (PBMC's) was suppressed
by > 50% at the fifth dose level (2.8 mg/kg) and best response of stable disease for > 2 months
was reported in 6 of 23 patients(46). A second phase Ib study reported safety and efficacy of
BSI-201 in combination with several DNA-damaging chemotherapeutic agents (i.e.
gemcitabine, topotecan, temozolomide, or carboplatin/paclitaxel). Among 66 treated patients
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(24 breast cancer patients), 2 serious adverse events were possibly related to BSI-201 and all
patients tolerated doses up to 5.6mg/kg. The addition of BSI-201 did not potentiate expected
toxicities of individual cytotoxics. Fifty-three of 66 reported some clinical benefit with partial
response observed in 2 advanced breast cancer patients(47).
Both the shared clinico-pathologic features between BRCA-deficient and sporadic TNBC and
preclinical evidence illustrating synergy for BSI-201 and gemcitabine/carboplatin provided
the rationale to investigate the efficacy of BSI-201 with chemotherapy in advanced TNBC
(15,16). One-hundred and twenty women with metastatic TNBC were enrolled in a multi-
center, open-label, randomized, clinical trial in the United States. Enrolled patients who had
received 0–2 prior lines of chemotherapy in the metastatic setting were randomized to receive
gemcitabine (1000mg mg/m2, IV, days 1, 8) plus carboplatin (AUC 2, IV, days, 1, 8) with or
without BSI-201 (5.6mg/kg, IV, days 1, 4, 8, 11) every 21 days. Clinical benefit rate (CR +
PR + SD [stable disease]) at 6 months and safety of combination therapy was the primary
objective of this trial. Secondary objectives included overall response rates, PFS and overall
survival (OS).
Patients' baseline characteristics were well-balanced between treatments arms. Notably, > 50%
of patients in both arms had received prior taxane and anthracycline-based chemotherapy and
10%, prior bevacizumab. Clinical benefit rates were superior among patients who received
BSI-201 in combination with chemotherapy compared to those who received chemotherapy
alone (62% versus 21%, respectively; p = 0.0002). In addition, PFS and OS was superior among
patients who received BSI-201 (6.9 versus 3.3 months; Hazard Ratio [HR] = 0.342, p <0.0001
and 9.2 versus 5.7 months; HR = 0.348, p = 0.0005, respectively)(15). An updated analysis
continues to confirm an OS advantage among patients who received BSI-201 in combination
with chemotherapy compared to chemotherapy alone (12.2 versus 7.7 months, p = 0.005;
Figure 2)(36). The updated safety analysis indicates the addition of BSI-201 does not potentiate
side effects of chemotherapy. Preliminary efficacy results prompted the design of an ongoing
multicenter, randomized, phase III trial to confirm efficacy of BSI-201 in combination with
gemcitabine/carboplatin chemotherapy, results of which are eagerly awaited.
Proposed Mechanisms for Resistance to PARP inhibition
PARP inhibitors have illustrated clinical efficacy in historically-challenging, often treatment-
refractory malignancies, however disease control rarely exceeds one year. Although not
entirely understood, resistance to PARP inhibitors is hypothesized to result from one of several
mechanisms including, but not limited to up-regulation of the multi-drug resistance (MDR 1,2)
efflux pumps(48) and reversion of BRCA mutation with restoration of BRCA function(49). A
series of several studies support the proposed mechanisms of PARP resistance.
Long-term treatment of a BRCA-1 deficient genetically engineered mouse model (GEMM)
treated with the PARP inhibitor, AZD2281, caused up-regulation of the Abcb1a/b genes
encoding for the P-glycoprotein efflux pumps, and occasionally up-regulation of the drug
target, PARP1. Moreover, resistance in all cases was reversed by co-administration of
tariquidar, a P-glycoprotein inhibitor(48). A separate series of experiments employed a PARP-
inhibitor-resistant clone from a human pancreatic cell line homozygous for the BRCA2 protein-
truncating c.6174delT frameshift mutation. Resistant cell lines were found to express new
BRCA2 isoforms as a result of intragenic deletion spanning the c.6174delT mutation, resulting
in restoration of the open reading frame, creating a novel BRCA2 allele functional for
homologous recombination and causing decreased sensitivity to PARP inhibition(49). Finally,
based on the knowledge that PARP inhibitors and platinum chemotherapeutics have
overlapping targets, platinum resistance may inform mechanisms of PARP inhibitor resistance.
Among a series of recurrent BRCA1 mutated ovarian cancers, 4 of 6 recurrent, platinum-
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resistant tumors had developed secondary genetic changes in BRCA1 that restored the open
reading frame of the BRCA1 protein, thus conferring diminished platinum sensitivity(50).
Although complex, rational strategies to circumvent the two flavors of PARP inhibitor
resistance, up-regulation of MDR efflux pumps and reversion mutations, may exist. Such
strategies will be challenging to translate clinically and underscore the need for tissue collection
from the numerous early phase clinical trials evaluating PARP inhibition in both BRCA-
mutated and non-BRCA-mutated advanced malignancies to study mechanisms of resistance.
Conclusions, Challenges and Future Directions
Results from elegant preclinical studies and promising clinical trials continue to highlight
PARP inhibitors as one of the most promising “targeted therapies” for aggressive TNBC. As
we as a medical community move forward, we are challenged with several tasks including
(1) more precisely defining the patient population (even within TNBC patient population) most
likely to respond to the PARP inhibition, (2) discovering and validating candidate biomarkers
to predict responders (i.e. (γ) H2AX, RAD51 [as a marker of intact HR], germline DNA studies,
etc.), (3) determining the optimal chemotherapy back-bone to combine with PARP inhibitors,
(4) defining the most effective schedule of administration (ie. continuous versus intermittent
dosing with chemotherapy), and finally, (5) moving PARP inhibitors into “niche” settings (i.e.
brain metastases arising from TNBC). In this era of personalized medicine, investigators are
actively working to further define TNBC patients most likely to respond to PARP inhibitors.
This is particularly important as these drugs move to the adjuvant setting since long-term
toxicities to normal tissues as a result of prolonged suppression of DNA repair have yet to be
defined. As an example, an as of yet unvalidated, but intriguing 25-gene assay was developed
to identify BRCA-like sporadic TNBC; an approach such as this may help us select patients
most likely to respond to this class of drugs (51). The role of PARP inhibitors in non-TNBC
phenotypes is also of interest since the mechanism of PARP inhibition may serve to sensitize
endocrine sensitive and/or HER2-positive breast tumors to DNA-damaging chemotherapy.
Each of the aforementioned challenges are areas deserving of further study and are the subject
of ongoing clinical investigation. Although challenging at first glance, thoughtful planning and
coordinated efforts between collaborating pre-clinical, translational, and clinical investigators
will continue to move the development of PARP inhibitors forward and hold the potential to
improve the lives of the hundreds and thousands of women diagnosed with breast cancer
worldwide each year.
Statement of Translational Relevance
The treatment of triple negative breast cancer with PARP inhibitors is a perfect example of
translational medicine. Close to a decade ago, investigators hypothesized that preventing
DNA repair via PARP inhibition, in conjunction with the loss of DNA-repair via BRCA-
dependent mechanisms, would result in synthetic lethality and augmented cell death. This
hypothesis has borne out in preclinical studies evaluating the effect of PARP inhibition on
BRCA-deficient cell lines and BRCA-deficient preclinical tumor models. Profound efficacy
observed in the preclinical arena was readily-transferrable to the clinical setting.
Recognizing the clinico-pathologic similarities between BRCA-deficient and triple negative
breast tumors (often termed “BRCA-ness”), PARP inhibitors have been tested in both patient
populations and illustrate apparent clinical efficacy. Future studies to define PARP inhibitor
mechanisms of resistance and response biomarkers to define optimal patient populations
will involve returning back to the bench, such that strides at the bedside continue – the
essence of translational medicine.
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Figure 1a: Two main pathways which contribute to repair of DNA double strand breaks: non-
homologous end joining (NHEJ) and homologous recombination (HR). This figure was
published in Abeloff's Clinical Oncology, 4th Edition. JM Ford and MB Kastan, Chapter 10:
DNA damage response pathways and cancer. p. 149. (Reprinted with permission, Copyright
2008, Churchill Livingstone, an Imprint of Elsevier) (5).
Figure 1b: ‘Synthetic lethality’ and subsequent cell death due to loss of parallel DNA repair
pathways. In the presence of one (or both) functional BRCA- or PARP-dependent DNA repair
pathways, cells survive. In the absence of both, cell death ensues (Reprinted with permission,
from EA Comen and M Robson: ONCOLOGY 24(1):55-68, 2010) (52).
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Kaplan Meier curves illustrating an overall survival advantage for patients with triple negative
metastastic breast cancer treated with the PARP inhibitor, BSI-201 (BiPAR Sciences/Sanofi
Aventis) plus carboplatin/gemcitabine chemotherapy compared to chemotherapy alone (12.2
versus 7.2 months, p = 0.005)(36).
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Table 1
Shared clinic-pathologic features between BRCA-1 deficient and triple negative/Basal-like breast cancer. Figure
adapted from 2009 ASCO Plenary Session(15).
Clinico-pathologic Characteristics Hereditary BRCA1 Breast Cancer Triple Negative/Basal-like Breast Cancer
ER/PR/HER2 status Negative Negative
TP53 status Mutant Mutant (Up to 80%)
BRCA1 status Mutational Inactivation Diminished Expression (?)
Gene-expression patterns Basal-like Basal-like
Tumor Histology Poorly-differentiated (high grade) Poorly-differentiated (high grade)
Chemosensivity to DNA-damaging chemotherapy Highly sensitive Likely sensitive
Genome-wide Aneuploidy Yes Yes
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Table 2
A summary of representative PARP inhibitors in clinical development by route of administration and current
clinical status.
Agent Company Route of Administration Clinical Status
Olaparib/(AZD2281) AstraZeneca/KuDOS Oral Phase 1 and 2
Veliparib/(ABT-888) Abbott Oral Phase 1 and 2
BS1-201 BiPar/SanofiAventis IV Phase 2 and 3
AG014699 Pfizer IV Phase 1 and 2
MK482 Merck Oral Phase 1
INO-1001 Inotek IV Phase 1
CEP9272 Cephalon Oral Phase 1
Clin Cancer Res. Author manuscript; available in PMC 2011 October 1.
